GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (NAS:NKGN) » Definitions » Total Stockholders Equity

NKGen Biotech (NKGen Biotech) Total Stockholders Equity : $-55.06 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is NKGen Biotech Total Stockholders Equity?

NKGen Biotech's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $-55.06 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. NKGen Biotech's Book Value per Share for the quarter that ended in Mar. 2024 was $-2.46. The ratio of a company's debt over equity can be used to measure how leveraged this company is. NKGen Biotech's Debt-to-Equity for the quarter that ended in Mar. 2024 was -0.40.

NKGen Biotech Total Stockholders Equity Historical Data

The historical data trend for NKGen Biotech's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NKGen Biotech Total Stockholders Equity Chart

NKGen Biotech Annual Data
Trend Dec21 Dec22 Dec23
Total Stockholders Equity
-38.05 1.56 -58.69

NKGen Biotech Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Total Stockholders Equity Get a 7-Day Free Trial 1.56 - -40.64 -58.69 -55.06

NKGen Biotech  (NAS:NKGN) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

NKGen Biotech's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-55.055-0)/22.389
=-2.46

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

NKGen Biotech's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(11.719 + 10.495) / -55.055
=-0.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NKGen Biotech Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of NKGen Biotech's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

NKGen Biotech (NKGen Biotech) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (NAS:NKGN) » Definitions » Total Stockholders Equity
Comparable Companies
OCUP CASI SPRO XLO NGM GBIO ASMB CCCC OCEA FIXX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
19700 Fairchild Road, Suite No. 300, Irvine, CA, USA, 92612
Website
https://www.nkgenbiotech.com
NKGen Biotech Inc is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapies utilizing our proprietary SNK (super-activated) platform.